High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens - PubMed (original) (raw)
. 2005 Jan 17;201(2):241-8.
doi: 10.1084/jem.20041379.
Wenbin Ma, Francesca Schiavetti, Christophe Lurquin, Emmanuelle Henry, Nathalie Vigneron, Francis Brasseur, Bernard Lethé, Etienne De Plaen, Thierry Velu, Thierry Boon, Pierre G Coulie
Affiliations
- PMID: 15657293
- PMCID: PMC2212796
- DOI: 10.1084/jem.20041379
High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens
Catherine Germeau et al. J Exp Med. 2005.
Abstract
After vaccination of melanoma patients with MAGE antigens, we observed that even in the few patients showing tumor regression, the frequency of anti-vaccine T cells in the blood was often either undetectable or <10(-5) of CD8 T cells. This frequency being arguably too low for these cells to be sole effectors of rejection, we reexamined the contribution of T cells recognizing other tumor antigens. The presence of such antitumor T cells in melanoma patients has been widely reported. To begin assessing their contribution to vaccine-induced rejection, we evaluated their blood frequency in five vaccinated patients. The antitumor cytotoxic T lymphocyte (CTL) precursors ranged from 10(-4) to 3 x 10(-3), which is 10-10,000 times higher than the anti-vaccine CTL in the same patient. High frequencies were also observed before vaccination. In a patient showing nearly complete regression after vaccination with a MAGE-3 antigen, we observed a remarkably focused antitumoral response. A majority of CTL precursors (CTLp's) recognized antigens encoded by MAGE-C2, another cancer-germline gene. Others recognized gp100 antigens. CTLp's recognizing MAGE-C2 and gp100 antigens were already present before vaccination, but new clonotypes appeared afterwards. These results suggest that a spontaneous antitumor T cell response, which has become ineffective, can be reawakened by vaccination and contribute to tumor rejection. This notion is reinforced by the frequencies of anti-vaccine and antitumor CTLs observed inside metastases, as presented by Lurquin et al. (Lurquin, C., B. Lethe, V. Corbiere, I. Theate, N. van Baren, P.G. Coulie, and T. Boon. 2004. J. Exp. Med. 201:249-257).
Figures
Figure 1.
Limiting dilution analysis of antitumor CTLp's in patient EB81. Lytic patterns obtained at days 20 and 27 with limiting dilution microcultures set up with 700 and 350 blood CD8 lymphocytes and stimulated with irradiated autologous tumor cells, IL-2, IL-4, and IL-7 on days 0, 7, 14, and 21. Microcultures deemed to contain specific antitumor T cells are boxed. The lytic activity of aliquots of the microcultures was measured against autologous tumor cells EB81-MEL, autologous EBV-transformed B cells (EB81-EBV), and K562. On day 20 only, effector cells and 51Chromium-labeled targets were incubated in the presence of a 50-fold excess of unlabeled K562 to quench the lytic activity of NK-like effectors. Microcultures were considered to contain antitumor CTLs if they satisfied on day 20 as well as on day 27 the following criteria: lysis of tumor >10% and lysis of EBV-B and K562 lower than one third of the lysis of tumor.
Figure 2.
Frequencies and target antigens of antitumor CTLs from patient EB81. The clinical evolution of the patient and the frequencies of antitumor and anti-vaccine CTLp's are indicated in the top. Frequencies of antitumor CTLp's were measured by MLTC with a tumor cell line derived from the invaded lymph node, whereas those of anti–MAGE-3.A1 and anti–MAGE-C2336–344 CTLp's were measured by clonotypic PCR. The bottom panels represent antitumor CTL clones with different numbers for each TCR sequence and the occurrence of repeated clones. Most of these CTL clones were derived from lymphocytes collected in September 1999 and March 2000 and were stimulated in autologous MLTC. Additional CTL clones were derived from lymphocytes collected in October 2000 by stimulation with MAGE-C2 peptides and identification of the positive microcultures with the appropriate tetramer. For peptide MAGE-C2336–344, 15 additional CTL clones were obtained. 14 turned out to be the CTL 16 clonotype, whereas one, CTL 40, had another TCR. A similar experiment performed with MAGE-C2191–200 revealed a new highly repeated clonotype, CTL 41.
Figure 3.
Lytic activity of antitumor CTL clones of patient EB81. Target cells included autologous melanoma cells EB81-MEL (•), autologous EBV-B cells (○), and K562 cells (▵).
Similar articles
- Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen.
Lurquin C, Lethé B, De Plaen E, Corbière V, Théate I, van Baren N, Coulie PG, Boon T. Lurquin C, et al. J Exp Med. 2005 Jan 17;201(2):249-57. doi: 10.1084/jem.20041378. J Exp Med. 2005. PMID: 15657294 Free PMC article. - Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen.
Lonchay C, van der Bruggen P, Connerotte T, Hanagiri T, Coulie P, Colau D, Lucas S, Van Pel A, Thielemans K, van Baren N, Boon T. Lonchay C, et al. Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2(Suppl 2):14631-8. doi: 10.1073/pnas.0405743101. Epub 2004 Sep 27. Proc Natl Acad Sci U S A. 2004. PMID: 15452345 Free PMC article. - Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases.
Corbière V, Chapiro J, Stroobant V, Ma W, Lurquin C, Lethé B, van Baren N, Van den Eynde BJ, Boon T, Coulie PG. Corbière V, et al. Cancer Res. 2011 Feb 15;71(4):1253-62. doi: 10.1158/0008-5472.CAN-10-2693. Epub 2011 Jan 7. Cancer Res. 2011. PMID: 21216894 - [General principles and first clinical trials of therapeutic vaccines against cancer].
Baurain JF, Van der Bruggen P, Van den Eynde BJ, Coulie PG, Van Baren N. Baurain JF, et al. Bull Cancer. 2008 Mar;95(3):327-35. doi: 10.1684/bdc.2008.0588. Bull Cancer. 2008. PMID: 18390413 Review. French. - Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.
Coulie PG, Karanikas V, Lurquin C, Colau D, Connerotte T, Hanagiri T, Van Pel A, Lucas S, Godelaine D, Lonchay C, Marchand M, Van Baren N, Boon T. Coulie PG, et al. Immunol Rev. 2002 Oct;188:33-42. doi: 10.1034/j.1600-065x.2002.18804.x. Immunol Rev. 2002. PMID: 12445279 Review.
Cited by
- VentX promotes tumor specific immunity and efficacy of immune checkpoint inhibitors.
Le Y, Gao H, Le J, Hornick JL, Bleday R, Wee J, Zhu Z. Le Y, et al. iScience. 2023 Dec 14;27(1):108731. doi: 10.1016/j.isci.2023.108731. eCollection 2024 Jan 19. iScience. 2023. PMID: 38299030 Free PMC article. - A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges.
Chen Y, Wang J, Zhang F, Liu P. Chen Y, et al. Front Pharmacol. 2023 Apr 19;14:1151032. doi: 10.3389/fphar.2023.1151032. eCollection 2023. Front Pharmacol. 2023. PMID: 37153761 Free PMC article. Review. - A New Plasmacytoid Dendritic Cell-Based Vaccine in Combination with Anti-PD-1 Expands the Tumor-Specific CD8+ T Cells of Lung Cancer Patients.
Hannani D, Leplus E, Laurin D, Caulier B, Aspord C, Madelon N, Bourova-Flin E, Brambilla C, Brambilla E, Toffart AC, Laulagnier K, Chaperot L, Plumas J. Hannani D, et al. Int J Mol Sci. 2023 Jan 18;24(3):1897. doi: 10.3390/ijms24031897. Int J Mol Sci. 2023. PMID: 36768214 Free PMC article. - Identification of TCR repertoires in functionally competent cytotoxic T cells cross-reactive to SARS-CoV-2.
Shimizu K, Iyoda T, Sanpei A, Nakazato H, Okada M, Ueda S, Kato-Murayama M, Murayama K, Shirouzu M, Harada N, Hidaka M, Fujii SI. Shimizu K, et al. Commun Biol. 2021 Dec 2;4(1):1365. doi: 10.1038/s42003-021-02885-6. Commun Biol. 2021. PMID: 34857854 Free PMC article. - Immunoprotective effect of an in silico designed multiepitope cancer vaccine with BORIS cancer-testis antigen target in a murine mammary carcinoma model.
Mahdevar E, Kefayat A, Safavi A, Behnia A, Hejazi SH, Javid A, Ghahremani F. Mahdevar E, et al. Sci Rep. 2021 Nov 30;11(1):23121. doi: 10.1038/s41598-021-01770-w. Sci Rep. 2021. PMID: 34848739 Free PMC article.
References
- Chomez, P., O. De Backer, M. Bertrand, E. De Plaen, T. Boon, and S. Lucas. 2001. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res. 61:5544–5551. - PubMed
- Boël, P., C. Wildmann, M.-L. Sensi, R. Brasseur, J.-C. Renauld, P. Coulie, T. Boon, and P. van der Bruggen. 1995. BAGE, a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity. 2:167–175. - PubMed
- De Backer, O., K.C. Arden, M. Boretti, V. Vantomme, C. De Smet, S. Czekay, C.S. Viars, E. De Plaen, F. Brasseur, P. Chomez, et al. 1999. Characterization of the GAGE genes that are expressed in various human cancers and in normal testis. Cancer Res. 59:3157–3165. - PubMed
- Lethé, B., S. Lucas, L. Michaux, C. De Smet, D. Godelaine, A. Serrano, E. De Plaen, and T. Boon. 1998. LAGE-1, a new gene with tumor specificity. Int. J. Cancer. 76:903–908. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous